Mediation of cardiovascular risk factor effects through subclinical vascular disease: The multi-ethnic study of atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 8, 2014, Pages 1778-1783

  Yeboah, Joseph ^a   Delaney, Joseph A ^b   Nance, Robin ^b   McClelland, Robyn L ^b   Polak, Joseph F ^c   Sibley, Christopher T ^d   Bertoni, Alain ^a   Burke, Gregory L ^a   Carr, J Jeffery ^e   Herrington, David M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular events; Carotid intima media thickness; Coronary artery calcium score; Flow mediated dilation; Risk factors

Indexed keywords

CARDIOVASCULAR EVENTS; CAROTID INTIMA-MEDIA THICKNESS; CORONARY ARTERY CALCIUM SCORE; FLOW-MEDIATED DILATION; RISK FACTORS;

AGE FACTORS; AGED; AGED, 80 AND OVER; ASYMPTOMATIC DISEASES; ATHEROSCLEROSIS; BODY MASS INDEX; BRACHIAL ARTERY; CARDIOVASCULAR DISEASES; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; ETHNIC GROUPS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NONLINEAR DYNAMICS; OBESITY; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SMOKING; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES; VASCULAR CALCIFICATION; VASODILATION;

EID: 84904619657     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.303753     Document Type: Article

References (21)

1. McGill HC Jr, McMahan CA, Gidding SS. Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. Circulation. 2008;117:1216-1227.
2. Fernandez-Britto JE, Wong R, Contreras D, Nordet P, Sternby NH. Pathomorphometrical characteristics of atherosclerosis in youth. A multinational investigation of WHO/World Heart Federation (1986 -1996), using atherometric system. Nutr Metab Cardiovasc Dis. 1999;9:210-219.
3. Berenson GS, Srinivasan SR, Bao W, Newman WP III, Tracy RE, Wattigney WA. Association between multiple cardiov ascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998;338:1650-1656.
4. McGill HC Jr, McMahan CA, Zieske AW, Sloop GD, Walcott JV, Troxclair DA, Malcom GT, Tracy RE, Oalmann MC, Strong JP. Associations of coronary heart disease risk factors with the intermediate lesion of athe rosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol. 2000;20:1998-2004.
5. Lüscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, Münzel T, Kastelein JJ, Deanfield JE; dal-VESSEL Investigators. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J. 2012;33:857-865.
6. Vergeer M, Zhou R, Bots ML, et al. Carotid atherosclerosis progression in familial hypercholesterolemia patients: a pooled analysis of the ASAP, ENHANCE, RADIANCE 1, and CAPTIVATE studies. Circ Cardiovasc Imaging. 2010;3:398-404.
7. Davidson MH. METEOR and ENHANCE: a tale of two CIMT trials: part Curr Cardiol Rep. 2008;10:479-480.
8. Gaziano JM, Wilson PW. Cardiovascular risk assessment in the 21st century. JAMA. 2012;308:816-817.
9. Hlatky MA. Framework for evaluating novel risk markers. Ann Intern Med. 2012;156:468-469.
10. Alexander RW. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension. 1995;25:155-161.
11. Stein CM, Morris NJ, Nock NL. Structural equation modeling. Methods Mol Biol. 2012;850:495-512.
12. Taylor AJ, Sullenberger LE, Lee HJ, Lee LK, Grace KA. Arterial biology for investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double blind, placebo-controlled study of extendedrelease niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512-3517.
13. Crouse JR III, Raichlen JS, Riley WA, Evans GW, Palmer MK, O' Leary DH, Grobbee DE, Bots ML; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297:1344-1353.
14. Wang JG, Staessen JA, Li Y, Van Bortel LM, Nawrot T, Fagard R, Messerli FH, Safar M. Carotid intima-media thickn ess and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke. 2006;37:1933-1940.
15. Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O'Leary D, Carr JJ, Goff DC, Greenland P, Herrington DM. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate- risk individuals. JAMA. 2012;308:788-795.
16. Kavousi M, Elias-Smale S, Rutten JH, et al. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med. 2012;156:438-444.
17. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 1995;91:2488-2496.
18. Hijmering ML, Stroes ES, Pasterkamp G, Sierevogel M, Banga JD, Rabelink TJ. Variability of flow mediated dilation: consequences for clinical application. Atherosclerosis. 2001;157:369-373.
19. Corti R, Fuster V. Imaging of atherosclerosis: magnetic resonance imaging. Eur Heart J. 2011;32:1709-1719b.
20. Muller JE, Abela GS, Nesto RW, Tofler GH. Triggers, acute risk factors and vulnerable plaques: the lexicon of a new frontier. J Am Coll Cardiol. 1994;23:809-813.
21. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126.